Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Sci Rep ; 10(1): 20110, 2020 11 18.
Article in English | MEDLINE | ID: mdl-33208899

ABSTRACT

Phosphatidylserine (PS) exposure is increased in red cells from sickle cell anaemia (SCA) patients. Externalised PS is prothrombotic and attractive to phagocytes and activated endothelial cells and thus contributes to the anaemic and ischaemic complications of SCA. The mechanism of PS exposure remains uncertain but it can follow increased intracellular Ca2+ concentration ([Ca2+]i). Normally, [Ca2+]i is maintained at very low levels but in sickle cells, Ca2+ permeability is increased, especially following deoxygenation and sickling, mediated by a pathway sometimes called Psickle. The molecular identity of Psickle is also unclear but recent work has implicated the mechanosensitive channel, PIEZO1. We used Yoda1, an PIEZO1 agonist, to investigate its role in sickle cells. Yoda1 caused an increase in [Ca2+]i and PS exposure, which was inhibited by its antagonist Dooku1 and the PIEZO1 inhibitor GsMTx4, consistent with functional PIEZO1. However, PS exposure did not necessitate an increase in [Ca2+]i. Two PKC inhibitors were also tested, chelerytherine chloride and calphostin C. Both reduced PS exposure whilst chelerytherine chloride also reduced Yoda1-induced increases in [Ca2+]i. Findings are therefore consistent with the presence of PIEZO1 in sickle cells, able to mediate Ca2+ entry but that PKC was also involved in both Ca2+ entry and PS exposure.


Subject(s)
Anemia, Sickle Cell/blood , Erythrocytes/metabolism , Phosphatidylserines/blood , Benzophenanthridines/pharmacology , Calcium/metabolism , Dose-Response Relationship, Drug , Erythrocyte Membrane/chemistry , Erythrocyte Membrane/drug effects , Erythrocytes/drug effects , Humans , Intercellular Signaling Peptides and Proteins/pharmacology , Ion Channels/antagonists & inhibitors , Ion Channels/metabolism , Protein Kinase C/antagonists & inhibitors , Protein Kinase C/blood , Pyrazines/administration & dosage , Pyrazines/pharmacology , Spider Venoms/pharmacology , Thiadiazoles/administration & dosage , Thiadiazoles/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL